CellWell record HH-331449
Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer
Freitas CSM; Rocha-Silva F; Marques-Silva TA; de Oliveira ACR; da Silva SG; Santos Cardoso FD; Soares AN
The Canadian journal of urology ยท 2026
In plain language
Leuprolide 22.5 mg achieved superior PSA reduction but higher rates of hot flashes; goserelin 10.8 mg showed greater testosterone variability and cardiovascular events.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-331449
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.